SCHEMBL21811367

SCHEMBL21811367

CNC(=O)c1nn(Cc2ccc(OC)cc2)c2cc(Br)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.53
ALOX15 P16050 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HDAC6 Q9UBN7 3/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
MAPK8 P45983 1/20 0.43
POLB P06746 2/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FPR1 P21462 1/20 0.41
FPR2 P25090 1/20 0.41
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PTGS2 P35354 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
PIK3R1 P27986 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902962 1.00 PTGER4 (0.53) PTGER4ALOX15L3MBTL1HDAC6HDAC1
SCHEMBL22914198 0.88 PTGER4 (0.48) PTGER4ALOX15L3MBTL1MAPK8POLB
SCHEMBL24149122 0.80 ELANE (0.56) PTGER4ALOX15L3MBTL1HDAC6MAPK8
SCHEMBL22913944 0.79 PDE5A (0.42) PTGER4MAPK8MEN1KMT2APTGS2
SCHEMBL16014218 0.78 CNR1 (0.45) MAPK8MAPTMEN1KMT2APTGS2
SCHEMBL24484019 0.78 CNR1 (0.45) ALOX15L3MBTL1MAPK8POLBMAPT
SCHEMBL10273212 0.78 LMNA (0.46) PTGER4HDAC6HDAC1HDAC2MAPT
SCHEMBL29670185 0.78 CNR1 (0.45) ALOX15L3MBTL1MAPK8POLBMAPT
SCHEMBL22912889 0.77 CNR1 (0.43) PTGER4MAPK8FPR1FPR2PTGS2
SCHEMBL5103746 0.77 CNR1 (0.44) PTGER4MAPK8MAPTKMT2APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12084426-B2 Indazole carboxamides as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-09-10 US disclosed
CN-112673001-B Indazole carboxamides as kinase inhibitors 百时美施贵宝公司 2024-06-25 CN disclosed
EP-3849969-B1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-04-19 EP disclosed
US-20210309633-A1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-10-07 US disclosed
EP-3849969-A1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2021-07-21 EP disclosed
CN-112673001-A Indazole carboxamides as kinase inhibitors 百时美施贵宝公司 2021-04-16 CN disclosed
WO-2020056074-A1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309633-A1 INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS RIPK3, RIPK1, RIPK2 PTGER4 2886/4885ALOX15 3775/4885L3MBTL1 3330/4885
US-12084426-B2 Indazole carboxamides as kinase inhibitors RIPK3, RIPK1, RIPK2 PTGER4 2886/4885ALOX15 3775/4885L3MBTL1 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.